View older revisions Content changed at 2021-07-05, 1400/04/14

Protocol summary

Study aim
Determination of effect of 8 weeks intervention with lavender-bergamot aroma, mindfulness counseling, aroma-mindfulness counseling on sexual function score, anxiety score, and levels of some serum bio-markers in postmenopausal women compared to control group
Design
A randomized controlled clinical trial with a factorial design, stratified by menopause duration. 132 postmenopausal women randomly will be divided into four groups of counseling based on mindfulness and aroma placebo, aromatherapy and routine care, counseling based on mindfulness and aromatherapy, and control group using Random Allocation Software (RAS) with 1:1:1:1 ratio.
Settings and conduct
Eligible women will be selected among health centers and randomly assigned into one of the four groups after giving written informed consent. Aroma and its similar placebo, 3 times daily, 2-3 drops on the skin for 8 weeks and counseling in 45-60 minutes sessions, once a week for 8 consecutive weeks will be administered.The blinding of researcher and participants in terms of counseling will not be possible
Participants/Inclusion and exclusion criteria
Inclusion criteria: Married postmenopausal women; Age between 50-60; Having records in Tabriz Elderly Friendly Centers; Mild to moderate anxiety; Sexual dysfunction score less than 28; PSQI 5 or more; Greene between 15-42. Exclusion criteria: Use of herbal compounds to increase libido in men or women; Sensitivity to any of the herbal remedies; Occurrence of the adverse event within 3 months prior to the study;
Intervention groups
The groups receiving counseling based on mindfulness and aromatherapy, aromatherapy and routine care, counseling based on mindfulness and aromatherapy, or control group (placebo of aroma and routine care)
Main outcome variables
Mean score of sexual function after intervention Mean score of anxiety after intervention Serum level of some bio-markers after intervention

General information

Reason for update
Hi, ]t is hereby conveyed that due to the coincidence of the implementation stages of this trial with the corona pandemic and its various peaks, the sampling process was prolonged and sampling was completed with a delay on 2020-11-21 instead of 2020-03-15. Therefore, we want to correct the completion date of sampling. Also, along with the studied variables, due to the importance of sleep quality and menopausal symptoms in menopausal women, these two variables were also considered as a secondary outcome along with other variables. Therefore, please agree with the above amendments. Thank you
Acronym
IRCT registration information
IRCT registration number: IRCT20131009014957N8
Registration date: 2019-12-04, 1398/09/13
Registration timing: registered_while_recruiting

Last update: 2021-07-05, 1400/04/14
Update count: 2
Registration date
2019-12-04, 1398/09/13
Registrant information
Name
Azizeh Farshbaf-khalili
Name of organization / entity
Tabriz university of Medical Sciences
Country
Iran (Islamic Republic of)
Phone
+98 41 1333 9151
Email address
farshbafa@tbzmed.ac.ir
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2019-11-22, 1398/09/01
Expected recruitment end date
2020-11-21, 1399/09/01
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Effect of aromatherapy with essential oil of lavender-bergamot, and counseling based on mindfulness on sexual function, anxiety, and serum level of some bio-markers in postmenopausal women: A randomized controlled trial with factorial design.
Public title
Effect of aromatherapy and counseling based on mindfulness on sexual function, anxiety, and serum level of some bio-markers in postmenopausal women
Purpose
Supportive
Inclusion/Exclusion criteria
Inclusion criteria:
Willingness to participate in the study Postmenopausal women between the ages of 50-60 Having read and write literacy The Female Sexual Function Score less than 28 Having mild to moderate anxiety based on Beck Anxiety Scale Having sex in the family limit with her permanent spouse Having only one wife for the man Natural menopause Obtaining a score of 15-42 on the Greene scale Having a score of 5 and higher in The Pittsburgh Sleep Quality Index (PSQI)
Exclusion criteria:
Known physical and mental illnesses based on person's self statement (depression, diabetes, cardiovascular disease, olfactory sensations, mental disability, diabetes) Drugs affecting sex (sildenafil, antidepressants, antihistamines, diazepines, barbiturates, amphetamines, antihypertensive drugs, cocaine, thiazide diuretics, narcotics Use of herbal ingredients to increase sexual desire in men or women (ginseng, cinnamon, ginger, etc.) and alergy to any herbal medicine Addiction to the habitual consumption of alcohol and tobacco by women Participate in other similar studies Occurrence of an misadventure within 3 months prior of study (death or acute illness of close relatives) Disorder in the sense of smell according to person's self and other nasal disorders (fracture, aberration, rhinitis) Use of hormotherapy at last 6 month
Age
From 50 years old to 60 years old
Gender
Female
Phase
3
Groups that have been masked
  • Outcome assessor
  • Data analyser
Sample size
Target sample size: 132
Randomization (investigator's opinion)
Randomized
Randomization description
Postmenopausal women aged 50-60 years will be divided into four groups of aromatherapy and routine care, counseling based on Mindfulness-Based Intervention (MBI) and aromatherapy, counseling based on MBI and placebo of aromatherapy, and control group (placebo of aromatherapy and routine care) using the RAS software with four and eight blocks with a 1: 1: 1: 1 allocation ratio and will be stratified based on menopausal years (less than or greater than 5 years). To conceal the allocated intervention, type of counseling intervention (counseling or routine care) will be written on papers and along with allocated aromas or placebo will be placed in the matte and sealed envelopes numbered from 1 to 132 based on random sequence generated by a non-researcher. The first envelope will be given to the first eligible person and will be continued until the completion of sampling. The participant, researcher and statistical analyst will not be aware of the contents of the package (allocation concealment). In this study, after the random allocation of the individual to the study group, the researcher and participant blindness would not be possible in terms of counseling,
Blinding (investigator's opinion)
Double blinded
Blinding description
In this study, outcome assessor and statistical analyst will be kept blind to the specific study groups. So that the combined aroma and its placebo will be poured into identical dark containers and identified only by random code of study. The outcome assessor and the statistical analyst will not be present at the consultation sessions. Questionnaires will not specify the type of intervention and only random code will be written. Also in the statistical software, only the code of the participants and the group number will be written.
Placebo
Used
Assignment
Factorial
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Ethics Committee of Tabriz University of Medical Sciences
Street address
Research Department., Third Floor., Central Construction Number 2., Tabriz University of Medical Sciences., Golgasht Street., Azadi Avenue
City
Tabriz
Province
East Azarbaijan
Postal code
5166614756
Approval date
2019-10-14, 1398/07/22
Ethics committee reference number
IR.TBZMED.REC.1398.749

Health conditions studied

1

Description of health condition studied
Anxiety
ICD-10 code
F41
ICD-10 code description
Other anxiety disorders

2

Description of health condition studied
Sexual dysfunction
ICD-10 code
F52
ICD-10 code description
Sexual dysfunction not due to a substance or known physiological condition

3

Description of health condition studied
Depression
ICD-10 code
F32
ICD-10 code description
Major depressive disorder, single episode

4

Description of health condition studied
Serum levels of some bio-markers
ICD-10 code
ICD-10 code description

5

Description of health condition studied
Menopausal symptoms
ICD-10 code
N95
ICD-10 code description
Menopausal and other perimenopausal disorders

6

Description of health condition studied
Sleep quality
ICD-10 code
G47
ICD-10 code description
Sleep disorders

Primary outcomes

1

Description
Anxiety score in Beck Anxiety Inventory
Timepoint
At baseline and 8 weeks after intervention
Method of measurement
Beck Anxiety Inventory

2

Description
Sexual function score in Female Sexual Function Index
Timepoint
At baseline and 8 weeks after intervention
Method of measurement
Female Sexual Function Index

3

Description
Serum level of cortisol
Timepoint
At baseline and immediately after intervention
Method of measurement
Elisa method by ELISA kits

Secondary outcomes

1

Description
Depression score using Beck Depression Inventory
Timepoint
At baseline and 8 weeks after intervention
Method of measurement
Beck Depression Inventory

2

Description
Serum level of malondialdehyde
Timepoint
َAt baseline and immediately after intervention
Method of measurement
By spectrophotometric method based on reaction with thiobarbituric acid

3

Description
Serum level of high-sensitivity C-Reactive Protein
Timepoint
َAt baseline and immediately after intervention
Method of measurement
Complex-based turbidometry based on the reaction between high-sensitivity C-Reactive Protein and specific antiserum

4

Description
Serum level of Total Antioxidant Capacity
Timepoint
َAt baseline and immediately after intervention
Method of measurement
By Autoanalyzer Abbott (Alcyon 300) using Randox kit

5

Description
Frequency of adverse events
Timepoint
While intervention
Method of measurement
Adverse events checklist

6

Description
Menopausal symptom score using Greene climacteric scale
Timepoint
At baseline and 8 weeks after intervention
Method of measurement
Greene Climacteric Scale

7

Description
The score of Pittsburgh Sleep Quality Index (PSQI)
Timepoint
At baseline and 8 weeks after intervention
Method of measurement
Pittsburgh Sleep Quality Index (PSQI)

Intervention groups

1

Description
Intervention group 1: Mindfulness consulting along with placebo of aroma. Mindfulness in-person counseling will be held once per week for eight weeks through the 45-60 minute sessions in a native language. The number of participants in each meeting will be at least eight and up to twelve. The last 15 minutes will be devoted to question and answer. Aroma placebo (probylene glycol) will be rubbed 2 to 3 drops, 2-3 times a day for 8 weeks. The placebo will be made by Goldaru Pharmaceutical Company and packed in 30 ml dark glass.
Category
Treatment - Other

2

Description
Intervention group 2: ََAromatherapy with essential oil of lavender-bergamot along with routine care. Lavender-bergamot essential oil will be applied 3 times daily, 2-3 drops each time for 8 weeks on the forearm. The composition of the essential oils will be in the form of 5% lavender and 0.4% bergamot essential oils. The pure essential oils will be provided by the Goldaru Pharmaceutical Company. The analysis of essential oils, blending of them with the desired concentration will be carried out in the Faculty of Pharmacy and will be packed in 30 ml dark glass.Routine care will be carried out in accordance with the Ministry's approved protocol.
Category
Treatment - Other

3

Description
Intervention group 3: Aromatherapy with essential oil of lavender-bergamot along with Mindfulness consulting. Lavender-bergamot essential oil will be applied 3 times daily, 2-3 drops each time for 8 weeks on the forearm. The composition of the essential oils will be in the form of 5% lavender and 0.4% bergamot essential oils. The pure essential oils will be provided by the Goldaru Pharmaceutical Company. The analysis of essential oils, blending of them with the desired concentration will be carried out in the Faculty of Pharmacy and will be packed in 30 ml dark glass. Mindfulness in-person counseling will be held once per week for eight weeks through the 45-60 minute sessions in a native language. The number of participants in each meeting will be at least eight and up to twelve. The last 15 minutes will be devoted to question and answer.
Category
Treatment - Other

4

Description
Control group: Placebo of aroma along with routine care. Aroma placebo (probylene glycol) will be rubbed 2 to 3 drops, 2-3 times a day for 8 weeks. The placebo will be made by Goldaru Pharmaceutical Company and packed in 30 ml dark glass. Routine care will be carried out in accordance with the Ministry's approved protocol.
Category
Placebo

Recruitment centers

1

Recruitment center
Name of recruitment center
Tabriz Elderly-friendly Health Centers
Full name of responsible person
Dr.Mitra Yeganeh
Street address
Nesfrah Square., Tabriz health center
City
Tabriz
Province
East Azarbaijan
Postal code
5157665633
Phone
+98 41 3444 0057
Email
yeghanehm@tbzmed.ac.ir

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Tabriz University of Medical Sciences
Full name of responsible person
Dr. Mohammad Samiei
Street address
No. 2 Central building of the university, Golgasht street, Azadi street
City
Tabriz
Province
East Azarbaijan
Postal code
5166614766
Phone
+98 41 3335 7310
Fax
+98 41 3334 4280
Email
research-vice@tbzmed.ac.ir
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Tabriz University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact
Name of organization / entity
Tabriz University of Medical Sciences
Full name of responsible person
Dr. Azizeh Farshbaf-Khalili
Position
Assistant Professor
Latest degree
Ph.D.
Other areas of specialty/work
Nutrition
Street address
Physical Medicine and Rehabilitation Research Center, Street, Ground Floor, Imam Reza Hospital, Golgasht Street
City
Tabriz
Province
East Azarbaijan
Postal code
5166614766
Phone
+98 41 3336 1928
Email
farshbafa@tbzmed.ac.ir

Person responsible for scientific inquiries

Contact
Name of organization / entity
Tabriz University of Medical Sciences
Full name of responsible person
Dr. Azizeh Farshbaf-Khalili
Position
Assistant Professor
Latest degree
Ph.D.
Other areas of specialty/work
Nutrition
Street address
Physical Medicine and Rehabilitation Research Center, Ground Floor, Imam Reza Hospital, Golgasht Street
City
Tabriz
Province
East Azarbaijan
Postal code
5166614766
Phone
+98 41 3336 1928
Email
farshbafa@tbzmed.ac.ir

Person responsible for updating data

Contact
Name of organization / entity
Tabriz University of Medical Sciences
Full name of responsible person
Dr. Azizeh Farshbaf-Khalili
Position
Asistant professor
Latest degree
Ph.D.
Other areas of specialty/work
Nutrition
Street address
Physical Medicine and Rehabilitation Research Center, Ground Floor, Imam Reza Hospital, Golgasht Street
City
Tabriz
Province
East Azarbaijan
Postal code
5166614766
Phone
+98 41 3336 1928
Email
farshbafa@tbzmed.ac.ir

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Yes - There is a plan to make this available
Study Protocol
Undecided - It is not yet known if there will be a plan to make this available
Statistical Analysis Plan
Undecided - It is not yet known if there will be a plan to make this available
Informed Consent Form
Yes - There is a plan to make this available
Clinical Study Report
Yes - There is a plan to make this available
Analytic Code
Undecided - It is not yet known if there will be a plan to make this available
Data Dictionary
Undecided - It is not yet known if there will be a plan to make this available
Title and more details about the data/document
Requested data will be provided to researchers for statistical analysis of the submitted proposal (meta-analysis).
When the data will become available and for how long
ُStarting immediately after publication
To whom data/document is available
Data will be available to researchers as well as to journals
Under which criteria data/document could be used
The data will be available to researchers upon request and submission of a proposal to perform meta-analysis using IPD data after being unidentified. Also, in exceptional cases, data will be made available to journals for checking
From where data/document is obtainable
Refer to the email address (farshbafa@tbzmed.ac.ir)
What processes are involved for a request to access data/document
The requests will be sent by email and data will be available within a week
Comments
Loading...